Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.09 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: venglustat, lucerastat, eliglustat tartrate +2 | 1.00 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 1 stopped | 0.20 |
| literature PubMed | 6 Parkinson's papers of 184 | 0.74 |
| pathways Reactome | 1 pathway; mostly lysosome and autophagy | 1.00 |
No case: the score is under the bar. Receipt 2879
Sealed predictions
- UGCG in dopamine neurons, braak-0.17 (p 0.656) → +0.02 (p 0.964)receipt 2886
Swarm cases
receipt 2886: UGCG in dopamine neurons, braak
- power
- full sample -0.24 (p 0.328, n 18), 95% CI -0.64 to +0.25. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.34 (p 0.173, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.29 (p 0.235, n 18). could be the mix.
- skeptic
- leave-one-out range -0.37 to -0.15, sign flips 0; without severely affected donors -0.24 (p 0.328, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for UGCG in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts